Literature DB >> 23467247

Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.

Joshua T Schiffer1, Lawrence Corey.   

Abstract

Herpes simplex virus-2 (HSV-2) is periodically shed throughout the human genital tract. Although a high viral load correlates with the development of genital ulcers, shedding also commonly occurs even when ulcers are absent, allowing for silent transmission during coitus and contributing to high seroprevalence of HSV-2 worldwide. Frequent viral reactivation occurs within ganglia despite diverse and complementary host and viral mechanisms that predispose toward latency, suggesting that viral replication may be constantly occurring in a small minority of neurons at these sites. Within genital mucosa, the in vivo expansion and clearance rates of HSV-2 are extremely rapid. Resident dendritic cells and memory HSV-2 specific T cells persist at prior sites of genital tract reactivation and, in conjunction with prompt innate recognition of infected cells, lead to rapid containment of infected cells. The fact that immune responses usually control viral replication in genital skin before lesions develop provides hope that enhancing such responses could lead to effective vaccines and immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467247      PMCID: PMC3981536          DOI: 10.1038/nm.3103

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  148 in total

1.  Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection.

Authors:  Laura K Mackay; Linda Wakim; Catherine J van Vliet; Claerwen M Jones; Scott N Mueller; Oliver Bannard; Douglas T Fearon; William R Heath; Francis R Carbone
Journal:  J Immunol       Date:  2012-01-23       Impact factor: 5.422

2.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection.

Authors:  Tao Peng; Jia Zhu; Khamsone Phasouk; David M Koelle; Anna Wald; Lawrence Corey
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

4.  Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.

Authors:  Elizabeth Tronstein; Christine Johnston; Meei-Li Huang; Stacy Selke; Amalia Magaret; Terri Warren; Lawrence Corey; Anna Wald
Journal:  JAMA       Date:  2011-04-13       Impact factor: 56.272

5.  Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.

Authors:  Zili Li; Senthilkumar Palaniyandi; Rongyu Zeng; Wenbin Tuo; Derry C Roopenian; Xiaoping Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

6.  The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.

Authors:  Joshua T Schiffer; Anna Wald; Stacy Selke; Lawrence Corey; Amalia Magaret
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

7.  Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior.

Authors:  Haile Selassie Okuku; Eduard J Sanders; Joyce Nyiro; Caroline Ngetsa; Eric Ohuma; R Scott McClelland; Matthew A Price; Susan M Graham
Journal:  Sex Transm Dis       Date:  2011-09       Impact factor: 2.830

8.  Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials.

Authors:  Christine Johnston; Misty Saracino; Steve Kuntz; Amalia Magaret; Stacy Selke; Meei-Li Huang; Joshua T Schiffer; David M Koelle; Lawrence Corey; Anna Wald
Journal:  Lancet       Date:  2012-01-04       Impact factor: 79.321

9.  Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-κB.

Authors:  Valerio Leoni; Tatiana Gianni; Stefano Salvioli; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

10.  Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity.

Authors:  Yiqi Guo; Magali Audry; Michael Ciancanelli; Laia Alsina; Joana Azevedo; Melina Herman; Esperanza Anguiano; Vanessa Sancho-Shimizu; Lazaro Lorenzo; Elodie Pauwels; Paul Bastard Philippe; Rebeca Pérez de Diego; Annabelle Cardon; Guillaume Vogt; Capucine Picard; Zafitsara Zo Andrianirina; Flore Rozenberg; Pierre Lebon; Sabine Plancoulaine; Marc Tardieu; Emmanuelle Jouanguy; Damien Chaussabel; Frederic Geissmann; Laurent Abel; Jean-Laurent Casanova; Shen-Ying Zhang
Journal:  J Exp Med       Date:  2011-09-12       Impact factor: 14.307

View more
  41 in total

Review 1.  Generating protective immunity against genital herpes.

Authors:  Haina Shin; Akiko Iwasaki
Journal:  Trends Immunol       Date:  2013-09-03       Impact factor: 16.687

2.  Herpes Simplex Virus 2 in Autonomic Ganglia: Evidence for Spontaneous Reactivation.

Authors:  Julianna R Pieknik; Andrea S Bertke; Philip R Krause
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

Review 3.  Tissue resident memory T cells and viral immunity.

Authors:  Pamela C Rosato; Lalit K Beura; David Masopust
Journal:  Curr Opin Virol       Date:  2016-12-14       Impact factor: 7.090

4.  Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection.

Authors:  Pedro M M Mesquita; Paula Preston-Hurlburt; Marla J Keller; Nalini Vudattu; Lilia Espinoza; Michelle Altrich; Kathryn Anastos; Kevan C Herold; Betsy C Herold
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

5.  HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates.

Authors:  Christopher D Petro; Brian Weinrick; Nazanin Khajoueinejad; Clare Burn; Rani Sellers; William R Jacobs; Betsy C Herold
Journal:  JCI Insight       Date:  2016-08-04

Review 6.  The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.

Authors:  Tiffany Kuo; Christine Wang; Tina Badakhshan; Sravya Chilukuri; Lbachir BenMohamed
Journal:  Vaccine       Date:  2014-10-16       Impact factor: 3.641

7.  IL-2 complex treatment amplifies CD8+ T cell mediated immunity following herpes simplex virus-1 infection.

Authors:  Naveen K Rajasagi; Barry T Rouse
Journal:  Microbes Infect       Date:  2016-11-17       Impact factor: 2.700

8.  A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2.

Authors:  Clare Burn; Natalie Ramsey; Scott J Garforth; Steven Almo; William R Jacobs; Betsy C Herold
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

Review 9.  Viral kinetic modeling: state of the art.

Authors:  Laetitia Canini; Alan S Perelson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-25       Impact factor: 2.745

Review 10.  Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Authors:  Christine Johnston; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.